Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

Homegrown Competition Looming

Listen to this article

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

first to hit the line — Innovent/GenFlee hit finish line for China's first approved KRAS G12C inhibitor • Source: Shutterstock

Innovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and domestic rivals to unlock a national market where roughly 50,000 patients are expected to be diagnosed with lung cancer harboring the drug’s targeted mutation in 2025.

Key Takeaways

Innovent/GenFleet's Dupert (fulzerasib) has outpaced foreign and domestic rivals to become China's first approved KRAS G12C inhibitor, for second-line NSCLC.

The conditional nod for Dupert, for the second-line treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC) and granted under...

Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

Jun 16 2026

A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

Embracing China’s Brave New Pharmaceutical World!

Dec 05 2025

• By Ellon Xu, Philip Leung, and Grace Shieh

Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Nov 12 2025

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Nov 12 2025

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

Oct 14 2025

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.